New Indication For Lenvima In India Spawns Opportunities For Many?
Executive Summary
Eisai’s lenvatinib is endorsed by an expert panel in India in combination with everolimus, for which multiple generic brands are available in addition to Novartis’ Afinitor. The Swiss multinational isn’t allying with Eisai in India at least for now.
You may also be interested in...
US FDA’s Project Orbis Could Streamline Global Clinical Trials In Cancer
Richard Pazdur tells the Pink Sheet that program for concurrent submission of oncology applications and collaborative review by global regulators also could speed approval in smaller countries; first applications under Project Orbis were for use of Lenvima/Keytruda combination for endometrial cancer in US, Canada, and Australia.
Eisai Taps Novartis Oncology Firepower For Lenvima
Following the recent approval of Lenvima for kidney cancer in the US, Eisai has allied with major oncology player Novartis to help drive sales of the product in this market.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.